Dzianis Babrou - Oasmia Pharmaceutical Head Devel

OASMYDelisted Stock  USD 0.06  0.00  0.00%   

Insider

Dzianis Babrou is Head Devel of Oasmia Pharmaceutical AB
Phone46 18 50 54 40
Webhttps://www.vivesto.com

Oasmia Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of (0.0875) % which means that it has lost $0.0875 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2542) %, meaning that it generated substantial loss on money invested by shareholders. Oasmia Pharmaceutical's management efficiency ratios could be used to measure how well Oasmia Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Michael HummelSTMicroelectronics NV ADR
60
Denise GrodeCirrus Logic
49
J ReeseSmall Cap Premium
60
Celine BerthierSTMicroelectronics NV ADR
N/A
Thomas ButtacavoliSmall Cap Premium
42
Todd SchivelyCedar Realty Trust
N/A
Todd SinaiSmall Cap Premium
50
Frank FilippsSmall Cap Premium
72
Dominique MielleSmall Cap Premium
51
Nicholas PartenzaCedar Realty Trust
N/A
Gilbert NathanSmall Cap Premium
40
Julius ErvingSmall Cap Premium
N/A
Lisha ParmarIris Acquisition Corp
39
Tyler HenshawKite Realty Group
N/A
Thomas MajorPyrophyte Acquisition Corp
37
Derrick BurksKite Realty Group
64
Dean PapadakisKite Realty Group
N/A
Andrea PetroSmall Cap Premium
68
Crystal PlumCedar Realty Trust
41
Remi OuazzaneSTMicroelectronics NV ADR
N/A
Jack RossSmall Cap Premium
62
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. Vivesto Ab operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 17 people. Oasmia Pharmaceutical AB [OASMY] is a Pink Sheet which is traded between brokers as part of OTC trading. Oasmia Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Oasmia Pharmaceutical Leadership Team

Elected by the shareholders, the Oasmia Pharmaceutical's board of directors comprises two types of representatives: Oasmia Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oasmia. The board's role is to monitor Oasmia Pharmaceutical's management team and ensure that shareholders' interests are well served. Oasmia Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oasmia Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kai Wilkinson, Chief Officer
Urban Ekelund, IR Mang
Henrik Rnnberg, Chief Health
John Cosby, Head Affairs
Robert Maiorana, Head CFO
Dzianis Babrou, Head Devel
Christer MD, Acting Officer
Reinhard Koenig, Chief Officer
Johanna Rostin, Head Affairs
Maria Hagberg, Head Affairs

Oasmia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oasmia Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Oasmia Pink Sheet

If you are still planning to invest in Oasmia Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oasmia Pharmaceutical's history and understand the potential risks before investing.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency